Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 7INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Papillomavirus Infections 2Virus Diseases 1Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × halofantrine × Clear all
NCT00541970 2018-08-17

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

GlaxoSmithKline

Phase 1 Completed
961 enrolled 43 charts
Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00426361 2018-07-20

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

GlaxoSmithKline

Phase 3 Completed
751 enrolled 22 charts

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡